Cogent Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COGT research report →
Range $45 – $55
Price Chart
About the company
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST).
- CEO
- Andrew R. Robbins
- IPO
- 2018
- Employees
- 258
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on COGT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.15B
- P/E
- -13.06
- Fwd P/E
- 33.99
- PEG
- -1.44
- P/S
- 0.00
- P/B
- 9.69
- EV/EBITDA
- -13.99
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -72.57%
- ROIC
- -50.09%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-4,619,000+0.0%
- Op Income
- $-333,363,000
- Net Income
- $-328,937,000-28.6%
- EPS
- $-2.04+12.1%
- OCF Growth
- -27.3%
- FCF Growth
- -27.7%
- 52W High
- $43.73
- 52W Low
- $13.78
- 50D MA
- $35.85
- 200D MA
- $36.33
- Beta
- 0.31
- RSI (14)
- 31
- Avg Volume
- 1.96M
No earnings-call transcripts are available for COGT yet.
- Free Float
- 86.9%
- Shares Outstanding
- 170.87M
- Float Shares
- 148.52M
of shares held by institutions
336 13F filers
Buy/sell ratio 8.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for COGT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Buy | Dec 12, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 25.68M | ▲ 2.56M |
| Blackrock, Inc. | 17.35M | ▲ 1.31M |
| Vanguard Group Inc | 11.51M | ▲ 3.76M |
| Vanguard Portfolio Management LLC | 8.07M | ▲ 739.08K |
| Vanguard Capital Management LLC | 7.41M | ▲ 517.37K |
| State Street Corp | 6.96M | ▲ 1.30M |
| Jupiter Topco LLC | 6.62M | ▲ 6.62M |
| Janus Henderson Group Ltd. | 5.97M | ▲ 1.43M |
| Fairmount Funds Management LLC | 5.50M | 0 |
| Deerfield Management Company, L.P. (Series C) | 5.01M | ▼ 4.04M |
| Tcg Crossover Management, LLC | 4.85M | ▼ 92.46K |
| Price T Rowe Associates Inc | 4.65M | ▲ 1.44M |
Held by 377 ETFs
Biggest fund positions in COGT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Ferrante Karen Jean | other | 759 |
| Aug 27, 26 | Morris Arlene | other | 3,583 |
| Aug 27, 26 | Morris Arlene | other | 41,927 |
| Aug 27, 26 | Morris Arlene | sell | 42,349 |
| Aug 27, 26 | Morris Arlene | other | 41,927 |
| Aug 27, 26 | Morris Arlene | sell | 3,161 |
| Aug 27, 26 | Morris Arlene | other | 3,583 |
| Jul 1, 26 | Ferrante Karen Jean | other | 627 |
| Jun 9, 26 | Harwin Peter Evan | other | 17,901 |
| Jun 9, 26 | Ferrante Karen Jean | other | 17,901 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COGT coverage
Recent articles, reports, and earnings notes.
No research on COGT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COGT report →Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Consensus Price Target of $51.56
defenseworld.net · Oct 1
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
globenewswire.com · Sep 15
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat
seekingalpha.com · Aug 27
Deutsche Bank AG Takes $10.32 Million Position in Cogent Biosciences, Inc. $COGT
defenseworld.net · Aug 24
Handelsbanken Fonder AB Purchases New Stake in Cogent Biosciences, Inc. $COGT
defenseworld.net · Aug 18
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
zacks.com · Aug 13
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
globenewswire.com · Aug 10
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
globenewswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.